PRINCETON JUNCTION, N.J., July 10 /PRNewswire/ -- Lutronic, Inc., one of the world's leading developers and manufacturers of aesthetic and medical laser systems, announced today that it has received regulatory clearance from the U.S. FDA (Food and Drug Administration) for the eCO2 system.
Using the proprietary Controlled Chaos Technology (CCT), this next-generation fractional CO2 laser is designed to offer a safe and innovative way to treat deep ablative indications such as resurfacing and coagulation of soft tissue, textural irregularities, fine lines, pigmented lesions, vascular dyschromia, and rhytides. The eCO2 has several features that offer customizable treatments that are easy to use and less painful to the patients.
Dr. J. David Holcomb, immediate past president of the Florida Society of Facial Plastic Surgeons, states that "the eCO2 is a familiar wavelength in an extremely elegant and versatile package, with the ability to perform incisional surgery, traditional ablative resurfacing and ablative microfractional photothermolysis."
Of particular interest to users is the ability to combine two operational modes in one delivery system, which is important when deep penetration and greater patient comfort is required. With both Static and Dynamic operation modes, users have the capability to stamp up to a 14x14mm scan area as well as the option to "feather" the treatment area to reduce the "checkerboard" appearance that is common with currently available fractional CO2 devices.
Further, at a 120 micron spot size, initial biopsy studies indicate that the laser can penetrate as deep as 2.4mm into the dermis. "We are seeing long-lasting and consistent results after just one treatment with the eCO2 system. Preliminary results show that patients may not need a follow-up treatment," says Jhung Won Hwang, Ph.D., Sr. Director, Regulatory Affairs, Lutronic, Inc.
With several international and U.S. patents pending, the eCO2 has add
|SOURCE Lutronic, Inc.|
Copyright©2008 PR Newswire.
All rights reserved